Add-on omalizumab improves day-to-day symptoms in inadequately controlled severe persistent allergic asthma.

摘要: Background:  Omalizumab is efficacious in the treatment of moderate-to-severe and severe persistent allergic (immunoglobulin E-mediated) asthma, reducing exacerbations, emergency visits improving quality life (QoL). However, as exacerbations are relatively infrequent, assessment efficacy on day-to-day symptoms warranted. Aims:  To investigate effect add-on omalizumab symptoms, how they correlate with QoL asthma. Methods:  The correlation between asthma symptom scores [Asthma Quality Life Questionnaire (AQLQ)] was assessed. Symptom-free days (total score = 0) symptom-controlled (definition 1: total score ≤1; definition 2: morning peak expiratory flow ≥90% baseline, daytime ≤1 night-time were compared omalizumab-treated group, responders placebo. Results:  Four hundred nineteen patients (omalizumab, n = 209; placebo, n = 210) included analyses, 61% (118/195) response data classified responders. Total strongly correlated AQLQ overall individual domains. well scores. Responders had significantly more symptom-free than placebo groups (45.8%, 37.2% 22.6% respectively), 56.1%, 47.9% 35.3%, respectively, 50.8%, 43.9% 28.0%, respectively). Conclusions:  In inadequately controlled QoL. Add-on improves placebo. Further improvement confirms physician’s a measure.